Furthermore, CD33+CD11b+HLA-DR−/low myeloid cells were shown to be expanded in the peripheral blood of CRC patients, with the number of circulating MDSCs positively correlating with poor prognosis and low survival rates (88). This evidence concerns the gene CD33 and colorectal carcinoma.